S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CVM Cel Sci Corporation New

0.6043

-0.0002 (-0.03%)

Nov 22 2024 - Closed

Delayed by 15 minutes

Form S-3 - Registration statement under Securities Act of 1933

nullnullnullnullnull

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Cel Sci Charts.

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Cel Sci Charts.

Cel Sci Corporation New News

Form 8-K - Current report
Friday 15 November 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Thursday 7 November 2024 (2 weeks ago) • Edgar (US Regulatory)

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Thursday 7 November 2024 (3 weeks ago) • Business Wire

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
Wednesday 30 October 2024 (4 weeks ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Friday 25 October 2024 (1 month ago) • Edgar (US Regulatory)

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Tuesday 22 October 2024 (1 month ago) • Business Wire

Form AW - Amendment Withdrawal Request
Thursday 10 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 months ago) • Edgar (US Regulatory)

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Tuesday 1 October 2024 (2 months ago) • Business Wire

More Cel Sci Corporation New News Articles

Capital for Colleagues

Queens Road Capital Inve... (PK)

Invesco Financials S&P U...

Investec Bnk 24

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions